Sharing Innovation in the Fight Against Neglected Tropical Diseases

www.wipoReSearch.org

World Intellectual Property OrganizationSecretariat

BIO Ventures for Global HealthPartnership Hub Administrator

Jennifer Dent – VP, Commercialization & Alliance Management

• WIPO Re:Search• Partnership Hub• WIPO Re:Search Resources• Database• Q&A

Agenda

2

• Led by the World Intellectual Property Organization in collaboration with BIO Ventures for Global Health

• Makes intellectual property, know-how and other resources available to Member researchers working in the neglected tropical disease, malaria and tuberculosis fields

• Provides free access and royalty free licenses– No upfront licensing fee– Royalty free products for Least Developed

Countries• Facilitates collaboration to develop new

drugs, vaccines, and diagnostics

What is WIPO Re:Search?

3

4

WIPO Re:Search is a voluntary Consortium governed by its Members and a set of Guiding Principles• WIPO – Secretariat • BVGH – Partnership Hub Administrator• Members – Contribute and access intellectual

property and other resources and partner to drive R&D for neglected tropical diseases, malaria and tuberculosis• Providers• Users• Supporters

WIPO Re:Search Roles

5

• Royalty-free licenses for neglected tropical disease, malaria and TB research and development for the least developed countries (LDCs)

• Members will consider in good faith the issue of access to these products for all developing countries, including those which do not qualify as LDCs

• Users shall be allowed to retain ownership of new intellectual property but are encouraged to make new inventions available through WIPO Re:Search

• License Agreements will be individually negotiated between Members in accordance with the Guiding Principles

Highlights of the Guiding Principles

6

Providers• Alnylam Pharmaceuticals• AstraZeneca• California Institute of Technology• Center for World Health & Medicine• Drugs for Neglected Diseases initiative• Eisai• Fundação Oswaldo Cruz (Fiocruz)• GlaxoSmithKline• Infectious Disease Research Institute (IDRI)• Liverpool School of Tropical Medicine• Massachusetts Institute of Technology• McGill University• Medicines for Malaria Venture• Merck• Northeastern University• Novartis• PATH• Pfizer• Sanofi• South African Medical Research Council• Stanford University• Swiss Tropical and Public Health Institute• University of California, Berkeley• University of Dundee

• U.S. National Institutes of Health• Walter Reed Army Institute of Research (WRAIR)

Potential Users• Anacor Pharmaceuticals• Center for World Health & Medicine• Drugs for Neglected Diseases initiative• Emory University• Fundação Oswaldo Cruz (Fiocruz)• Galvmed• Infectious Disease Research Institute (IDRI)• iThemba Pharmaceuticals• Liverpool School of Tropical Medicine• McGill University• Medicines for Malaria Venture• National Center for Genetic Engineering and Biotechnology (BIOTEC)• Northeastern University• PATH• Sabin Vaccine Institute• South African Medical Research Council• Stanford University• University of California, Berkeley• University of California, San Francisco• University of Dundee• Walter Reed Army Institute of Research (WRAIR)

WIPO Re:Search Providers & Users

7

Supporters

• Africa Fighting Malaria• Association of University Technology Managers• Biotechnology Industry Organization (BIO)• Council on Health Research for Development (COHRED)• Indian Council for Medical Research• International Federation of Pharmaceutical Manufacturers

& Associations (IFPMA)• Kenya Medical Research Institute• Licensing Executive Society International• Mahidol University• South African Medical Research Council• U.S. Patent and Trademark Office• Walter Reed Army Institute of Research (WRAIR)• World Health Organization (WHO)

WIPO Re:Search Supporters

8

21 Neglected Diseases

Buruli Ulcer Lymphatic filariasis

Chagas disease (American trypanosomiasis) Onchocerciasis

Cysticercosis Rabies

Dengue/dengue hemorrhagic fever Schistosomiasis

Dracunculiasis (guinea-worm disease) Soil transmitted helminthiasis

Echinococcosis Trachoma

Endemic treponematoses (Yaws) Podoconiosis

Foodborne trematode infections Snakebite

Human African trypanosomiasis Malaria

Leishmaniasis Tuberculosis

Leprosy

9

The Partnership Hub is the partnering component of WIPO Re:Search• Facilitate collaborations between members to

drive the development of drugs, vaccines and diagnostics for neglected tropical diseases, malaria and tuberculosis

• Recruit new Members• Actively engage with members to learn about

contributions and research needs• Build relationships with members to support their

partnering interests

The Partnership Hub

10

How does BVGH establish WIPO Re:Search collaborations?• Field member requests• Proactively identify partnership opportunities• Build knowledge of member contributions and

research programs• Match contributions and resources with member’s

research needs• Facilitate collaboration between members

BVGH - The Partnership Hub Administrator

11

Providers

• Contribute IP & know-how

• Collaborate• Host & Mentor

Users

• Search WIPO Re:Search database

• Identify & communicate resource needs

• CollaboratePartnership Hub Administrator

• Identify collaboration opportunities

• Connect Users & Providers

• Support Members

Partnership Hub: Connecting the Spokes

User

Provider

User

Provider

Provider

User

12

• Various research agreements • material transfer agreements – compound libraries,

compounds• confidentiality agreements - sharing data, know-how

and other confidential information• Building expertise and capacity through hosting and

mentoring arrangements

• Licensing agreements• Other agreements to support the development of

products for NTDs, malaria and tuberculosis

WIPO Re:Search Collaborations

13

• Partnership Hub Monthly Snapshot• Partnership Hub activities• Collaborations in the pipeline• Research requests• New and highlighted contributions• Select upcoming member presentations

• Quarterly Contribution Highlights• Two page scientific piece highlighting a WIPO

Re:Search contribution

Partnership Hub Resources

14

• Communications “tool-kit”• WIPO Re:Search slide set• One page overview for scientists • One page overview for policy makers• WIPO Re:Search flyer/brochure• WIPO Re:Search scientific poster• List of key neglected tropical disease meetings

• WIPO Re:Search Database

Partnership Hub Resources

15

WIPO Re:Search provides a searchable, public database of intellectual property, know-how and other resources

• Compounds

• Compound libraries

• Technologies

• Know-how and therapeutic area expertise

• Hosting and mentoring scientists at various research and development sites

• Coaching scientists

WIPO Re:Search Database

Structured search by…

Provider

Disease

Type of data

Q&A

19

AstraZeneca and iThemba• iThemba developing isocitrate lyase inhibitors for Tuberculosis• AstraZeneca is open to considering neglected tropical disease

research requests to support computational and predictive chemistry needs

• iThemba expressed interest in accessing computational support to improve DMPK properties

Potential Collaborations

About 1.9 billion people have latent TB. According to the WHO approximately 1.4 million people died of TB in 2010.

20

McKerrow Lab at UCSF interested in statins for Schistosomiasis

• Interest in compounds selective for parasite not human• Pharmaceutical companies such as Merck have developed statins

and are exploring availability of compound libraries for UCSF• Statins going off patent

Potential Collaborations

Schistosomiasis is caused by parasitic worms>207 million affected, 85% in Africa (WHO)

21

Emory Vaccine Center and Sabin Vaccine Institute• Emory scientists have expertise in system vaccinomics (how

vaccines affect innate and adaptive immunity and biomarker identification).

• Sabin is developing hookworm, schistosomiasis and Chagas vaccines.

• Potential to collaborate to better understand vaccine effect on immunity and to improve vaccine design.

Potential Collaborations

22

Alnylam• More than 1,500 issued or pending RNAi patents, with know-how and

expertise

AstraZeneca (AZ)• Host and mentor researchers working on NTD targets at AZ facilities• Screening of targets against AZ compound libraries

GlaxoSmithKline (GSK)• Contributed full antimalarial dataset (13,500 compounds)• Tres Cantos Open Lab Program

Merck• Casein Kinase I Inhibitors against Leishmaniasis (lead series)• Histone Deacetylase (HDAC) inhibitor series - malaria

Check out http://www.wipo.int/research/en/search/ for additional contributions

Selected Contributions in Database